CNETS Board Member Awareness

By |2021-11-05T04:34:17-04:00November 4th, 2021|Awareness|

CNETS Board Member Awareness Patient Education and Fundraising A core function of CNETS is to offer the Canadian neuroendocrine cancer community useful, [...]

Comments Off on CNETS Board Member Awareness

Pewter Zebra Keyfobs/Pendants

By |2021-09-11T09:23:41-04:00August 23rd, 2021|Awareness, News|

Volunteers create one-of-a-kind handmade Pewter Zebra Keyfobs/Pendants to help raise awareness & funds for CNETS Al Gillis is a neuroendocrine cancer patient and member of the Toronto Patient and [...]

Comments Off on Pewter Zebra Keyfobs/Pendants

Temozolomide Access in Ontario

By |2021-07-07T21:48:16-04:00July 6th, 2021|Treatment News|

CNETS is pleased to share the news that the oral chemotherapy drug, temozolomide, often used in combination with capecitabine, known as the CAPTEM regimen, is now more accessible to [...]

Comments Off on Temozolomide Access in Ontario

Lutathera Funded in Saskatchewan

By |2021-07-06T18:30:28-04:00July 6th, 2021|Treatment News|

As of June 1, 2021, Lutathera is now available in Saskatchewan. The reimbursement criteria is for patients with unresectable, well-differentiated midgut* neuroendocrine tumors (NET) in patients who have experienced [...]

Comments Off on Lutathera Funded in Saskatchewan

LUTATHERA Funded In British Columbia

By |2021-05-30T15:16:40-04:00March 8th, 2021|Treatment News|

CNETS is happy to announce that BC Cancer will now reimburse LUTATHERA for the approved indication. The BC Cancer Benefit Drug List, Published March 2021, Tumour Site: Gastrointestinal Peptide [...]

Comments Off on LUTATHERA Funded In British Columbia
Go to Top